Tag: MRD

Cold Spring Harb Mol Case Stud. 2023 Apr; 9(2): a006256. ,1,2 ,1,2 ,1,2 ,2,3 ,4 and 1,2 Mahvish Q. Rahim 1Pediatric Hematology Oncology, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA; 2Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, USA; April Rahrig 1Pediatric Hematology Oncology,…

NEW YORK – New findings presented at the American Society of Clinical Oncology in Chicago this week have offered a glimpse into a potential future for blood-based minimal residual disease tests in patients with sarcomas, a challenging application for liquid biopsy technologies due to a lack of recurring or predictable…

The measurable residual disease (MRD) assessment provides an attractive predictor of alloHCT outcomes. Cell-free DNA (cfDNA) has been applied to diagnosis, early detection, and disease burden monitoring in various tumors but its utility as an MRD test in myeloid malignancies has not been systematically evaluated. We sought to determine the…

Ciltacabtagene autoleucel (cilta-cel), a BCMA-targeting chimeric antigen receptor (CAR) T-cell therapy, may significantly slow or stop the progression of multiple myeloma (MM)  when compared with standard-of-care treatments among patients for whom lenalidomide no longer works, according to new data presented at the ASCO Annual Meeting 2023. The global, phase 3…

Moderna’s move into personalised cancer therapy continues to proceed at a rapid pace, with Merck & Co-partnered melanoma vaccine mRNA-4157 heading for a pivotal phase 3 programme after a phase 2b data drop at ASCO. In the study, mRNA-4157 (V940) – which targets dozens of unique tumour-associated antigens or neoantigens…

Source/Disclosures Published by: Source: Shah NN, et al. Abstract 7554. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago. Disclosures: Adaptive Biotechnology and a grant from the Froedtert Foundation supported this study. Shah reports consultant/advisory board roles with, research funding/paid expenses from or stock ownership in Adaptive…

mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of distant metastasis or death by 65% (HR=0.347 [95% CI, 0.145-0.828]); one-sided p value=0.0063) compared to KEYTRUDA alone The DMFS results, a key secondary endpoint of the Phase 2b KEYNOTE-942 study, will be presented at the 2023 American Society of Clinical…

NEW YORK – Invivoscribe and Complete Genomics said on Friday that they have inked a worldwide partnership to develop and commercialize oncology biomarker tests using Complete Genomics’ next-generation sequencing platforms. Financial details of the agreement were not disclosed. As part of the collaboration, Invivoscribe will be responsible for the development…

Invivoscribe and Complete Genomics said Friday that they are partnering to develop and commercialize biomarker tests. Under the terms of the deal, Invivoscribe will be responsible for the development of biomarker tests, including test controls and associated bioinformatics software. The tests will run on Complete Genomics’ next-generation sequencing (NGS) platforms….

New data emphasizes the value of MRD testing in predicting survival outcomes and informing the personalized treatment of patients with hematologic cancers clonoSEQ continues to be the MRD test of choice for biopharma companies as evidenced in over a dozen investigational studies across multiple therapeutic approaches SEATTLE, June 02, 2023…

SAN DIEGO and SAN JOSE, Calif. , June 2, 2023 /PRNewswire/ — Invivoscribe and Complete Genomics announced today that they had entered a partnership to develop and commercialize biomarker tests on Complete Genomics’ NGS platforms. The territory is worldwide, and the field is oncology and cancer research. Under the terms…

Precision BioSciences Provides Update on Allogeneic CAR T Programs and Regulatory Path Forward Details Category: DNA RNA and Cells Published on Thursday, 01 June 2023 10:51 Hits: 155 Azer-Cel Safety Profile was Significantly Improved Compared to Prior Cohorts in Patients Dosed Using Optimized Product at Lower Intensity Lymphodepletion; No Grade…

In 2020, there were more than 73,000 people living with acute myeloid leukemia (AML) in the United States. Approximately 31% of those with AML are estimated to survive 5 or more years after their diagnosis.1 Although a bone marrow transplant may increase that 5-year survival rate, the efficacy of the…

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here. Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and CeGaT GmbH, a global provider of…

May 24, 2023 | The Association for Molecular Pathology releases recommendations for germline variants detected by NGS, 10x Genomics wins German injunction against NanoString Technologies, and Revvity—formerly PerkinElmer—announces new license agreement with AstraZeneca. Plus new products and deployments from DNA Script, Thermo Fisher, Model N, GenScript, and more. Clear Labs…

Rates of relapse and worse survival were associated with persistent FLT3-ITD or NPM1 variants prior to allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia. Detection by DNA sequencing of persistent FLT3-ITD or NPM1 variants – the two most common AML variants – in blood ahead of allogeneic hematopoietic cell transplantation (allo-HCT)…

NEW YORK – Personalis said Tuesday that it has partnered with Ono Pharmaceutical and Japan’s National Cancer Center to assess its minimal residual disease platform in a study of Opdivo (nivolumab) in resectable rectal cancer with mismatch repair deficiency. Opdivo was jointly developed by Ono and Bristol Myers Squibb. During…

NEW YORK – A jury in the US District Court for the District of Delaware on Monday awarded Natera $19.4 million in damages for royalties and lost profits in a patent lawsuit against Invitae and ArcherDx. Specifically, the jury found that Invitae and ArcherDx products infringed upon Natera’s patents 10,557,172; 10,597,708; and 10,731,220;…

Sarclisa (isatuximab), given on top of standard treatment with Kyprolis (carfilzomib) and the steroid dexamethasone, was found to delay disease progression by almost three years, on average, in people with relapsed or refractory — hard-to-treat — multiple myeloma, according to updated data from a Phase 3 clinical trial. These results corresponded…

Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D’Amico TA, et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. J Natl Compr Canc Netw. 2021;19(3):254–66. Article  CAS  PubMed  Google Scholar  Aberle DR, Adams AM, Berg CD, Black WC,…

Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT LAWRENCEVILLE, N.J., May 11, 2023 (GLOBE NEWSWIRE) — IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines,…

Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT LAWRENCEVILLE, N.J., May 11, 2023 (GLOBE NEWSWIRE) — IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines,…

Patients At data cut-off (January 14, 2022), the median follow-up was 44 months; 49 (27.4%) patients in the Isa-Kd arm and 11 (8.9%) in the Kd arm were still on treatment (Fig. 1). The most frequent reason for discontinuation in both arms was progressive disease, although it was less frequent…

Treatment of T-ALL IF. (A) Swimmer plot displaying postinduction treatment of patients with IF split by trial. Standard chemotherapy indicates standard trial treatment. Nelarabine indicates nelarabine given either alone or in combination with other agents. High-dose chemotherapy indicates other non–nelarabine-containing regimens, most commonly FLA-IDA. (B) Kaplan-Meier plot showing OS of…

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the…

Houston, May 03, 2023 (GLOBE NEWSWIRE) — NuProbe, a genomics company developing ultrasensitive research assays for detecting and monitoring low-frequency mutations, gene fusions, and copy number alterations (CNAs), recently published research demonstrating capabilities of their blocker displacement amplification (BDA) technology for detection of a JAK2 mutation using qPCR. The research, done…

NEW YORK – Personalis said Tuesday that it has partnered with the Academic Breast Cancer Consortium (ABRCC) and Criterium to carry out a prospective clinical trial evaluating the clinical performance of its NeXT Personal test in patients with early-stage triple-negative breast cancer (TNBC). The firm’s assay, a tumor-informed blood test,…

Genomics company ChromaCode on Thursday announced a partnership with research and diagnostics company MedGenome to bring ChromaCode’s High Definition PCR (HDPCR) multiplexing technology to India and the Middle East. The HDPCR approach uses ChromaCode’s cloud-based analysis platform for deep multiplexing of actionable biomarkers in a single rapid assay for multiple…

Michael Andreeff, MD, PhD The E-selectin inhibitor uproleselan (GMI-1271) has shown preliminary efficacy in patients with acute myeloid leukemia (AML), and E-selectin could represent one of several novel targets for treatment of this patient population, according to Michael Andreeff, MD, PhD. Previously, a phase 1/2 trial (NCT02306291) investigating uproleselan plus…

Survivorship after the diagnosis and treatment of cancer is a uniquely uncertain state of being, one in which periods of relief are punctuated by uncertainty. Even while all indications suggest the cancer is gone, many patients can’t help but feel a sense of foreboding, as though the cancer had merely…

BOZEMAN, Mont., April 24, 2023 /PRNewswire/ — ALERCELL, INC. announced today that it has introduced a molecular Leukemia diagnostic platform. LENA Molecular Dx Leukemia Platform is a core group of 12 molecular diagnostic tests specialized in Leukemia early diagnostic, treatment guidance and MRD (Minimal residual disease) monitoring. All the tests…

Background: CARTITUDE-4 is a global, phase 3, randomized, controlled trial (NCT04181827) of ciltacabtagene autoleucel (cilta-cel), a dual-binding, B-cell maturation antigen-targeting chimeric antigen receptor (CAR)-T cell therapy, versus (vs) standard of care (SOC; pomalidomide, bortezomib, and dexamethasone [PVd] or daratumumab, pomalidomide, and dexamethasone [DPd]) in lenalidomide-refractory patients. Aims: To report results…

NEW YORK – Cancer detection and monitoring firm C2i this week shared a suite of new study results on its platform for minimal residual disease detection and monitoring using AI and whole-genome sequencing. The company, which launched as a joint venture between New York Genome Center (NYGC) and Weill Cornell…

The following is a summary of “Reproducibility of low-level residual myeloma immunoglobulin detection using ultra-deep sequencing,” published in the March 2023 issue of Hematology by Cédile et al.  The second most prevalent hematologic malignancy is multiple myeloma, a neoplasm of mature B-cells. Despite the progress in therapeutic interventions, the ailment…

DiaCarta, Ltd. Abstracts demonstrating XNA technology’s improvements to assay sensitivity across different technology platforms and support for use in companion diagnostics (CDx) assay development Additional abstracts to further support XNA technology’s potential for use in minimal residual disease (MRD) monitoring of residual cancer cells PLEASANTON, Calif., April 16, 2023 (GLOBE…

Adela’s platform demonstrated strong detection for early stage cancers FOSTER CITY, Calif., April 16, 2023 /PRNewswire/ — Adela, Inc. presented data today demonstrating the ability of its genome-wide methylome enrichment platform to detect a broad set of diverse cancers in early stages (stage I and II), when treatment can be…

Matthew S. Davids, MD, MMSc The combination of acalabrutinib (Calquence) plus venetoclax (Venclexta) is being investigated for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL) in the phase 3 MAJIC study (NCT05057494).1  Multiple effective treatment regimens exist for patients with previously untreated CLL, but research has not…

Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK Christopher Abbosh, Alexander M. Frankell, Selvaraju Veeriah, Sophia Ward, Kristiana Grigoriadis, Kevin Litchfield, Clare Puttick, Dhruva Biswas, Takahiro Karasaki, James R. M. Black, Carlos Martínez-Ruiz, Maise Al Bakir, Emilia L. Lim, Ariana Huebner, David A. Moore, Elizabeth Manzano, Crispin T. Hiley, Mariam Jamal-Hanjani, Abigail Bunkum, Antonia Toncheva, Corentin Richard, Cristina Naceur-Lombardelli, Foteini Athanasopoulou, Francisco Gimeno-Valiente, Haoran Zhai, Jie Min Lam, Kerstin…

The clonoSEQ Assay detects and quantifies specific DNA sequences found in malignant cells. Credit: mwooten from Pixabay. US-based Adaptive Biotechnologies (Adaptive) has formed a translational collaboration with Japanese pharmaceutical company Takeda to use its clonoSEQ Assay in the clinical trials across the latter’s haematologic malignancy portfolio. The collaboration will use…

Rojansky R, Cha M-Y, Chan DC (2016) Elimination of paternal mitochondria in mouse embryos occurs through autophagic degradation dependent on PARKIN and MUL1. eLife 5:e17896. doi.org/10.7554/eLife.17896 CrossRef  CAS  PubMed  PubMed Central  Google Scholar  Wei W, Pagnamenta AT, Gleadall N et al (2020) Nuclear-mitochondrial DNA segments resemble paternally inherited mitochondrial DNA…

The preliminary results from a whole genome minimal residual disease (MRD) test were evaluated in 31 patients with locally advanced rectal cancer (LARC). C2i Genomics and Memorial Sloan Kettering performed a collaborative study as part of the Organ Preservation for Rectal Adenocarcinoma (OPRA) trial. The test was evaluated for the…

The use of high sensitivity DNA sequencing tests to measure residual disease in AML could improve identification of patients at risk for relapse or death. “In acute myeloid leukemia (AML), the association between measurable residual disease (MRD)—leukemic cells remaining in a patient during clinical remission but not detectable by standard…

In patients with acute myeloid leukemia (AML) in first remission, the persistence of certain DNA variants related to measurable residual disease (MRD) prior to allogeneic hematopoietic cell transplant (HCT) was associated with post-HCT relapse and worse survival outcomes in a recent study. The findings, published in JAMA, suggest that the…

Background Cell-free DNA (cfDNA) refers to fragments of DNA released into the circulation by endothelial cells and white blood cells by active release or passively through apoptosis and necrosis.1,2 The fraction of cfDNA that originates from tumor is known as circulating tumor DNA (ctDNA). In 2016 the first commercial ctDNA…

Despite an initial increase in the amount of cell-free DNA (cfDNA) 2 weeks after surgery, high cfDNA levels do not negatively affect the accuracy of minimal residual disease (MRD) detection via circulating tumor DNA (ctDNA) in patients with colorectal cancer (CRC). This finding supports the earlier application of ctDNA testing,…

Primary Objectives: -to determine the tolerability of brentuximab vedotin given in combination with standard chemotherapy (ALCL99) and to determine the tolerability of crizotinib given in combination with chemotherapy (ALCL99) to estimate the event free survival (EFS) of Arm BV and Arm CZ and contrast these to historical control data Secondary…

doi: 10.1093/nar/gkad208. Online ahead of print. Chongwei Bi  1 , Lin Wang  1 , Yong Fan  2 , Baolei Yuan  1 , Gerardo Ramos-Mandujano  1 , Yingzi Zhang  1 , Samhan Alsolami  1 , Xuan Zhou  1 , Jincheng Wang  3 , Yanjiao Shao  4 , Pradeep Reddy  4 , Pu-Yao Zhang  5 , Yanyi Huang  3   6 , Yang Yu  5…

Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., March 30, 2023 (GLOBE NEWSWIRE) — IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, today announced financial results for the year ended December 31, 2022, and provided an update on its…

Carolyn Owen, MD, associate professor in the Division of Hematology & Hematological Malignancies, University of Calgary, and hematologist at the Tom Baker Cancer Center, discusses data from the phase 3 GLOW study (NCT03462719) which were presented at the 10th Annual Meeting of the Society of Hematologic Oncology (SOHO). The GLOW…

PRESS RELEASE Published March 16, 2023 FT MYERS, FL / ACCESSWIRE / March 16, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today the commercial availability of the RaDaR® assay, a liquid biopsy test for molecular/minimal residual disease (MRD). MRD is…

NEW YORK – Lipid nanoparticles that inhibit cellular uptake of cell-free DNA (cfDNA) and engineered antibodies that protect cfDNA from degradation are showing early success in boosting liquid biopsy cfDNA yields, which could eventually lead to improved cancer diagnostic and prognostic assays. Investigators from the Broad Institute and the Koch…

ADC Therapeutics SA 2022 Annual Report Table of Contents Letter to Shareholders Business Update Financial Review Corporate Governance Report from the Auditor on the Consolidated IFRS Financial Statements Consolidated IFRS Financial Statements for the Year Ended December 31, 2022 Report from the Auditor on the Statutory Financial Statements of ADC…

Recent studies have suggested that circulating tumor DNA (ctDNA) testing has prognostic value in colorectal cancer, but researchers maintain that additional studies are needed to confirm whether and how ctDNA testing should be used in practice.  A study published in Nature Medicine showed that ctDNA testing can identify patients with…

Entered into a €40 million credit facility with the European Investment Bank and closed an approximatively $25 million follow-on equity offering to support Cellectis’ research, development and innovation activities Positive preliminary clinical data from Phase 1 BALLI-01 study (evaluating UCART22) for patients with r/r B-cell ALL presented…

NEW YORK – Using DNA sequencing to detect measurable residual disease (MRD) in acute myeloid leukemia (AML) patients about to undergo a stem cell transplant can help predict who will have their disease recur, according to a new study by researchers at the US National Heart, Lung, and Blood Institute…

Autolus Therapeutics plc Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) B-cell Acute Lymphoblastic Leukemia (ALL) met the primary endpoint in the pivotal Phase 2 FELIX study and is on track for next data update at a medical conference in mid-2023 with a Biologics License Application (BLA) submission to the…

Importance: Preventing relapse for adults with acute myeloid leukemia (AML) in first remission is the most common indication for allogeneic hematopoietic cell transplant. The presence of AML measurable residual disease (MRD) has been associated with higher relapse rates, but testing is not standardized. Objective: To determine whether DNA sequencing to…

NEW YORK – Personalis said Tuesday that it is continuing a collaboration with AstraZeneca to explore the cancer sequencing firm’s Next Personal molecular residual disease (MRD) test in clinical research and drug development.  The two companies are evaluating the sensitivity and specificity of whole-genome-informed circulating tumor DNA testing that supports…

Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) B-cell Acute Lymphoblastic Leukemia (ALL) met the primary endpoint in the pivotal Phase 2 FELIX study and is on track for next data update at a medical conference in mid-2023 with a Biologics License Application (BLA) submission to the US FDA planned…

News Release Tuesday, March 7, 2023 A small portion of adults in remission from a deadly blood cancer had persisting mutations that were detected, which predicted their risk of death from having the cancer return. Researchers at the National Institutes of Health show the benefits of screening adult patients in remission from acute…

The use of the precision cellular therapy Orca-T demonstrated promising efficacy effects at a median follow-up of 1 year in patients with acute leukemia or high-risk myelodysplastic syndrome (MDS) in an early analysis of a phase 1b and 2 study that have yet to be reported, according to data presented…

An independent data monitoring committee (IDMC) has recommended that a phase 3 trial (NCT03616470) evaluating uproleselan (GMI-1271) plus chemotherapy for patients with relapsed/refractory acute myeloid leukemia (AML) should continue to the planned overall survival (OS) event trigger.1 The IDMC conducted an interim utility analysis using a very high statistical threshold…

NEW YORK – Calling its minimal residual disease (MRD) business “firing on all cylinders,” Adaptive Biotechnologies on Tuesday laid out a multitiered strategy to help expand utilization of its ClonoSeq MRD assay in lymphoid cancer patients. “To further increase ClonoSeq penetration, we are focused on a three-pronged strategy,” Adaptive CEO…

Early detection (pancreatic cancer) cfMeDIP-seq, 5hmC sequencing LR elastic-net Hierarchical clustering, t-SNE, LR with elastic-net penalization Methylation (5mC-5hmC) 208 (72/136) 24-feature 5mC, 27-features 5hmC, 51-features combined model SML, UML Combined 5mC and 5hmC AUC of 0.997 (sensitivity 0.938, specificity 0.955) Median total reads: 17.4 M, 0.8 nonduplicate mapping rate pms.cd120.com/PDAC/index.html…

Background Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive subtype of non-Hodgkin lymphoma and the Epstein–Barr virus (EBV), which is believed to play an important role in lymphomagenesis (1), is usually detected in malignant cells. Despite an improvement in treatment strategies including non-anthracycline-based chemotherapy, the disease recurs or progresses in…

J. Clin. Med. 2023, 12(4), 1438; doi.org/10.3390/jcm12041438 (registering DOI) J. Clin. Med. 2023, 12(4), 1438; doi.org/10.3390/jcm12041438 (registering DOI) Received: 25 October 2022 / Revised: 16 January 2023 / Accepted: 6 February 2023 / Published: 10 February 2023 Round 1 Reviewer 1 Report Dear Authors,Thank you for an interesting review. Please find attached…

Richters and DLBCL after CLL in 2013 After CLL diagnosed in 2013, unmutated, Trisomie 12, CD 38 neg., started FCR 6 cycles in Uni Clinic Cologne (Prof Hallek) up to 4/2014. MRD neg and CR. Then 9 years without therapy living well, no side effects. Now, in Oct 2023 the…

Expert oncologists review key updates regarding metastatic colorectal cancer from recent meetings and discuss their implications on real-world clinical practice. At a recent Around the Practice program hosted by CancerNetwork®, experts discussed the use of molecular and genetic testing to better treat patients with metastatic colorectal cancer (CRC). The panel…

SAN FRANCISCO — In patients who have undergone surgery for colorectal cancer, monitoring levels of circulating tumor DNA (ctDNA) in the weeks after the operation can provide prognostic information.  For example, patients who showed ctDNA positivity during the molecular residual disease (MRD) time window of 2-8 weeks and during surveillance…

Like most diseases, cancer does not have a one-treatment-cures-all solution. Patients with the same type of cancer can respond very differently to the same treatment, or respond differently over time, necessitating more personalized treatment plans. The development of next-generation sequencing (NGS) has made the sequencing of patient tissues or tumors…

Stacey A. Cohen, MD, associate professor, the Clinical Research Division, Fred Hutchinson Cancer Center, assistant professor, the Division of Oncology, the University of Washington, discusses the investigation of the optimal timing to test for circulating tumor DNA (ctDNA) to detect minimal residual disease (MRD) following surgery in patients with stage…

CORALVILLE, Iowa–(BUSINESS WIRE)–To help researchers accurately measure circulating tumor DNA (ctDNA) from the most degraded and low-input samples, Integrated DNA Technologies today launched a complete MRD workflow for tumor-informed approaches. The launch expands access to IDT’s xGen MRD Hybridization Panel and xGen cfDNA & FFPE DNA Library Preparation Kit, which…

Key subgroups of patients with newly diagnosed, transplant-eligible multiple myeloma (NDMM) who were treated with daratumumab and a well-known triplet regimen had improved responses—including progression free-survival (PFS)—compared with similar patients receiving only the triplet, according to a post hoc analysis of the phase 2 GRIFFIN study (NCT02874742).1 The analysis, which…

BALTIMORE – Researchers from the New York Genome Center and Weill Cornell Medicine and their collaborators have demonstrated the utility of Ultima Genomics’ sequencing platform for sensitive blood-based cancer monitoring, using whole-genome error-corrected sequencing of circulating cell-free DNA (ccfDNA) at high coverage. In a preprint posted on BioRxiv last year, the…

TORONTO, Jan. 24, 2023 /PRNewswire/ -Geneseeq Technology Inc. announced that Geneseeq’s multi-cancer minimal residual disease detection (MRD) and multi-cancer early detection (MCED) kits were both CE Marked for liquid biopsy use in solid tumor patients. Geneseeq Logo (CNW Group/Geneseeq Technology Inc.) The markings will enable Geneseeq to expand its global…

Investigators say they have uncovered a potential new biomarker that could help physicians better assess the risk of relapse in patients treated for acute lymphoblastic leukemia (ALL). This new method relies on the analysis of cell-free DNA (cfDNA) to detect the presence of ALL in patients, which investigators say could…

EQS-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIND Analysis at ASH 2022 10.12.2022 / 23:01 CET/CESTThe issuer is solely responsible for the content of this announcement. Media Release   PLANEGG/MUNICH, Germany, December 10, 2022   MorphoSys Presents Updated Tafasitamab…

Joseph E Maakaron, assistant professor of medicine, Marie Hu, assistant professor of medicine, Najla El Jurdi, assistant professor of medicine University of Minnesota Twin Cities, Minneapolis, United States Correspondence to: maaka001{at}umn.edu Abstract Chimeric antigen receptor T cells have revolutionized the treatment of hematological malignancies during the past five years, boasting…

Lai, L. et al. Production of alpha-1,3-galactosyltransferase knockout pigs by nuclear transfer cloning. Science 295, 1089–1092. doi.org/10.1126/science.1068228 (2002). ADS  CAS  Article  PubMed  Google Scholar  Kuwaki, K. et al. Heart transplantation in baboons using alpha1,3-galactosyltransferase gene-knockout pigs as donors: initial experience. Nat. Med. 11, 29–31. doi.org/10.1038/nm1171 (2005). CAS  Article  PubMed  Google…

Circulating cell-free DNA (cfDNA) is fragmented extracellular DNA, which is released from apoptotic and necrotic cells in small fragments of <200 bp [1]. cfDNA is typically isolated from the blood stream; however, it is also possible to detect cfDNA in other biological fluids such as urine or cerebrospinal fluid [2, 3,…

NEW YORK — Fortis Life Sciences, a provider of capital and other resources to life science tool companies, said on Tuesday that it has signed a deal to distribute AccuGenomics’ SNAQ-SEQ internal standards technology for next-generation sequencing in the US and Europe. Under the terms of the deal, Waltham, Massachusetts-based…

Researchers reported a favorable efficacy and manageable safety profile in anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for adults with B-cell lymphomas. Their data is presented in Frontiers in Genetics. Researchers, led by Wenyujing Zhou, aimed to determine the benefits and risks of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy…

The problem here is that you are comparing training metrics for XGBoost to CV metrics for AutoML models. The code you posted for the manual XGBoost models provides training metrics. Instead, you will need to grab the CV metrics if you want to make a fair comparison to the performance…

December 11-14, 2021; Atlanta, Georgia Results of this study showed that substantial proportions of clinical relapses were radiographically detected in asymptomatic patients, whereas immunosequencing MRD monitoring demonstrated suboptimal sensitivity. Format: Microsoft PowerPoint (.ppt) File Size: 484 KB Released: December 16, 2021 …

“Our longstanding relationship with the NSABP, through our work to develop and validate the Oncotype DX Breast Recurrence Score® and Colon Recurrence Score® tests, represents a remarkable collaboration between academic and industry partners. This relationship has fueled major advancements in understanding the role of molecular profiling in breast and colon…

A novel liquid biopsy test has been shown to distinguish between patients with neurofibromatosis type 1 (NF1) who have benign plexiform neurofibroma (PN) precursor lesions from patients who have malignant peripheral nerve sheath tumors (MPNST), say authors of a multi-institutional cross-sectional study. “Transformation from PN to MPNST is challenging to…

Stochastic Amplicon Ligation. DNA samples for oncology sequencing are typically extracted from FFPE tissues and can have average lengths of less than 500 nt due to accumulated chemical damage [18]. We developed the Stochastic Amplicon Ligation (SAL) method to enzymatically concatenate many short DNA molecules together to utilize the long-read…

CANCER & SINGLE-CELL ANALYSIS The heterogeneity and dynamism of cancer present formidable challenges to understanding and treating the disease. As discussed in the last section, tumor evolution often leads to considerable genetic variation across clones. But the complexity of tumors does not stop at the level of DNA. Intratumoral phenotypic…